Radiopharm Theranostics Advances 177Lu-RAD204 Trial with Higher Dose Approval

Trial Progress and Dose Escalation

Radiopharm Theranostics has marked a significant milestone in its clinical development program with the completion of patient enrollment for the second cohort in its Phase 1 dose escalation trial of 177Lu-RAD204. This radiopharmaceutical targets PD-L1 positive advanced cancers, a group of malignancies that includes non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, cutaneous melanoma, head and neck squamous cell carcinoma, and endometrial cancer.

The Data Safety Monitoring Committee has reviewed the safety data from the first two cohorts and approved advancing to a higher dose of 90 millicuries (mCi) for the third cohort. This decision reflects confidence in the compound’s tolerability and preliminary indications of tumor targeting, a crucial step in dose escalation studies aiming to find the optimal therapeutic window.

Early Safety and Tumor Uptake Signals

Initial data from patients in the first two cohorts have demonstrated encouraging tumor uptake of 177Lu-RAD204, suggesting the compound effectively homes in on PD-L1 expressing tumors. Moreover, the safety profile has been described as favorable, with no unexpected adverse events reported to date. This is particularly important given the advanced stage and limited treatment options for the patient population involved.

RAD204 is a single-domain monoclonal antibody labeled with Lutetium-177, designed to deliver targeted radiation to cancer cells expressing PD-L1. This approach not only aims to directly kill tumor cells but also to potentially overcome resistance mechanisms that limit the effectiveness of current immunotherapies.

Broader Implications and Next Steps

Radiopharm’s basket trial design, which includes multiple tumor types, reflects a strategic effort to address a broad spectrum of PD-L1 positive cancers. The company’s CEO, Riccardo Canevari, highlighted the potential for RAD204 to significantly improve clinical outcomes for patients facing life-limiting diseases with few effective treatments.

Looking ahead, the company will continue to monitor safety and efficacy signals as it administers the higher 90mCi dose in the third cohort. The data generated will be critical in guiding further clinical development, including potential Phase 2 studies and regulatory discussions.

Radiopharm Theranostics remains a clinical-stage player with a diversified pipeline of radiopharmaceuticals targeting solid tumors, underscoring its commitment to innovation in oncology therapeutics.